- ProMIS Neurosciences (PMN) has filed a registration statement with the United States SEC in connection with its Nasdaq application
- The listing of the company’s common shares on Nasdaq is subject to satisfaction of the listing requirements and approval by the Nasdaq exchange
- ProMIS Neurosciences, Inc. is a development-stage biotechnology company
- ProMIS Neurosciences Inc. (PMN) opened trading at C$ 0.10
ProMIS Neurosciences (PMN) has filed a registration statement with the U.S. Securities and Exchange Commission in connection with its Nasdaq application.
Eugene Williams, Chairman and CEO of ProMIS, commented on the news.
“With this important step, we are entering the final stages of a transformation of ProMIS begun last year, first with capital formation and now with a potential listing on NASDAQ. Our lead therapeutic candidate for Alzheimer’s disease, PMN310, is progressing well, and after written pre-IND feedback from the FDA remains on track for an IND filing by the end of the year.
We remain optimistic that clinical data in the Alzheimer’s field, specifically the pivotal trial data from Eisai’s lecanemab study, will be positive and could reverse the negative sentiment that resulted from the EMA and CMS decisions about Aduhelm. That positive data could benefit the entire AD field, including ProMIS. We also have been expanding and advancing our broader portfolio, continuing to apply the unique capabilities of our technology platform in addressing misfolded protein diseases. We believe that Nasdaq, with its tremendous depth and breadth of investment capital guided by scientific savvy, is the right stock exchange to fully appreciate the value of the ProMIS portfolio.”
The listing of the company’s common shares on Nasdaq is subject to satisfaction of the listing requirements of Nasdaq and approval of the listing by the exchange.
ProMIS Neurosciences, Inc. is a development-stage biotechnology company.
ProMIS Neurosciences Inc. (PMN) opened trading at C$ 0.10.
